Investor Presentaiton

49 Investor presentation Full year 2022 Novo Nordisk global insulin market leadership at 46.7% and the global insulin volume market declined by 0.9% North America Operations Market growth: -2.6% MS: 38.4% MS gain/loss': -0.2%-p Sales growth: -21% USA Market growth: -2.6% MS: 38% MS gain/loss': -0.1%-p Sales growth: -22% Global Market growth: -0.9% MS 46.7% MS gain/loss': -0.4%-p Sales growth: -11% Novo NordiskⓇ International Operations Market growth: -0.3% MS: 49.6% MS gain/loss: -0.6%-p Sales growth: -7% Market growth: -4.3% MS: 57.1% MS gain/loss': -0.2%-p Sales growth: 5% Region China Market growth: 6.9% MS: 48.5% MS gain/loss¹: -2.2%-p Sales growth: -22% EMEA Market growth: -1.1% MS: 47.4% ROW MS gain/loss: -0.1%-p Sales growth: -3% Source: IQVIA MAT, Nov 2022 volume figures Note: Sales growth for full year 2022 at constant exchange rates; Market shares are for Novo Nordisk, market growth for total insulin market 1MS gain/loss compared with Nov 2021 reported MS EMEA: Europe, Middle East and Africa; MS: Market share; ROW: Asia Pacific; Latin America; MS: Market Share; Region China covers Mainland China, Taiwan, and Hong Kong

View entire presentation